Immunome, Inc. (IMNM) Stock Forecast
IMNM analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.69 / 5 from 16 analysts
- Price target
- $35.19 average of analyst targets
- Upside to target
- +113.6% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.68
- 52-week range
- $15.24 – $29.82
IMNM analyst ratings
16 analystsNumber of analysts at each rating.
IMNM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
IMNM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.59 | −$0.71 | −$0.41 | −$0.65 | +8.9% | 15 |
| Current fiscal year (2026) | −$2.29 | −$2.56 | −$2.02 | −$2.43 | +5.6% | 14 |
| Next fiscal year (2027) | −$2.48 | −$3.13 | −$1.85 | −$2.29 | −8.1% | 13 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
IMNM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $133,330 | $0 | $2.0M | 0.0% | 15 |
| Current fiscal year (2026) | $266,670 | $0 | $4.0M | −96.2% | 15 |
| Next fiscal year (2027) | $50.4M | $5.7M | $109.8M | +18,804.0% | 14 |
IMNM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
IMNM revenue: reported and forecast
IMNM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.56 | −$0.59 | −$0.59 | −$0.59 | −$0.59 | +6.2% | 3 up · 7 down |
| Current fiscal year (2026) | −$2.12 | −$2.31 | −$2.31 | −$2.29 | −$2.29 | +8.0% | 0 up · 10 down |
| Next fiscal year (2027) | −$2.12 | −$2.48 | −$2.48 | −$2.43 | −$2.48 | +17.0% | 1 up · 7 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
IMNM earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; IMNM beat in 3 of 12.
What analysts expect from IMNM
16 analysts cover Immunome; their consensus rating is strong buy (4.69 on a 1–5 scale, where 5 is a strong buy). The average price target is $35.19, 113.6% above the latest close of $16.47. Analysts expect earnings of −$2.29 per share for 2026, +5.6% from a year earlier. For 2027 the average estimate is −$2.48 per share on revenue of $50.4 million. Immunome beat the EPS estimate in 3 of the last 12 quarters.
Related: IMNM income statement, IMNM key metrics, IMNM chart. See the IMNM stock overview for the latest quote and news.
IMNM forecast FAQ
What is Immunome's price target?
The average analyst price target for Immunome is $35.19, 113.6% above the latest close of $16.47.
Is Immunome a buy, hold or sell?
Of 16 analysts covering Immunome, 12 rate it a strong buy, 3 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Immunome's EPS forecast?
Analysts forecast −$2.29 per share for 2026 (range −$2.56 to −$2.02); for 2027 the estimate is −$2.48.
What is Immunome's revenue forecast?
The average revenue estimate for 2026 is $0.3 million, growth of −96.2%; for 2027 it is $50.4 million.
When does Immunome report earnings?
Immunome is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.68.
Does Immunome usually beat earnings estimates?
Immunome reported EPS at or above the analyst estimate in 3 of the last 12 quarters.